Grants and Contributions:
Title:
Development Rapid Diagnostic Test for COVID-19 (SARS-CoV-2)
Agreement Number:
947650
Agreement Value:
$307,764.00
Agreement Date:
Apr 1, 2020 - May 31, 2021
Description:
DASL RAPIDTM, a molecular diagnostic assay platform, will be used to develop a rapid test for SARS-CoV-2 in fluids collected from throat and nasal swabs. The prototype will be transferable for scale-up in public health laboratories or point-of-care systems.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Toronto, Ontario, CA M9W 4Z4
Reference Number:
172-2020-2021-Q1-947650
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
867782351
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 92 days.
Amendment Date
Feb 11, 2021
Recipient's Operating Name:
Custom Biologics
Recipient's Legal Name:
MJMG Holdings Inc. O/A Custom Biologics
Federal Riding Name:
Etobicoke North
Federal Riding Number:
35029
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: